Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURIER Finland
2012-001398-97Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, hypercholesterolemia and cardiac morbidity comparing Evolocumab + statin therapy with Placebo + statin therapy (2 arms). Primary endpoint: Time to first major cardiovascular event. Started Jun 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemiahypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2012-001398-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001398-97.